On March 20, 2023 Nex-I reported that it signed a business agreement (MOU) with Arontier for joint research and development of AI-based antibody new drugs (Press release, NEX-I, MAR 20, 2023, View Source;mode=VIEW&num=39&category=&findType=&findWord=&sort1=&sort2=&page=2 [SID1234643436]). The signing ceremony was attended by key officials of Nexi, including Nexi CEO Kyung-wan Yoon, Nexi Chief Operating Officer Jin-beop Son, Arontier CEO Ko Jun-soo, and Arontier Chief Strategy Officer Son In-seok.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The goal of this MOU is to improve NexI’s antibody new drug development method using AD3, an AI-based innovative new drug development platform developed by Arontier, to discover more efficient and precise new drug candidates.
Junsu Ko, CEO of Arontier, said, "Arontier can handle target protein structure and candidate material exploration at the same time, and through this collaboration, data and preclinical data such as Arontier’s AI-based interpretation technology and Nexi’s immune anticancer drug refractoriness inducers are available. "We will be able to use our research experience to obtain competitive results," he said.
Kyung-wan Yoon, CEO of Nexi, said, "Through this collaboration, both companies will be able to create results in the development of new antibody drugs by converging their respective technological capabilities," and added, "We expect that more accurate and rapid development will be possible using AI technology."
Meanwhile, Nexi is a biotech that develops new antibody drugs targeting immunotherapy refractory inducers, and is expected to lead solid cancers such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and malignant melanoma in 2024. We plan to enter phase 1 clinical trials for the pipeline ‘NXI-101’.